• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    I-Mab Rebrands as NovaBridge Biosciences, Trading as NBP Oct 30

    GLOBENEWSWIRE

    I-Mab To Present Updated Givastomig Data At AACR-NCI-EORTC

    GLOBENEWSWIRE

    I-Mab Unveils New Name, Strategy, Asset And Hong Kong IPO Plans

    FIERCE BIOTECH

    I-Mab to Rebrand as NovaBridge, Pursue Global Biotech Pivot

    GLOBENEWSWIRE

    I-Mab to Present on Updated Givastomig Monotherapy Data

    GLOBENEWSWIRE

    I-Mab Speeds Up Givastomig Investment and Leadership Changes

    GLOBENEWSWIRE

    I-Mab Appoint Biotech Executives to Board and Scientific Advisory

    GLOBENEWSWIRE

    I-Mab Attending September Investor Conferences

    GLOBENEWSWIRE

    I-Mab Reveals Q2 2025 Financial Results and Business Update

    GLOBENEWSWIRE

    I-Mab Completes Ph 1b Enrolls for Givastomig in 1L Gastric Cancer

    GLOBENEWSWIRE

    I-Mab prices $65M underwritten offering of American Depositary

    GLOBENEWSWIRE

    Everest Medicines Expands Strategic Investment in I-MAB

    PR NEWSWIRE

    I-Mab bolsters Givastomig IP portfolio with Bridge Health

    GLOBENEWSWIRE

    I-Mab to Speak at BTIG Virtual Biotech Conference

    GLOBENEWSWIRE

    I-Mab Presents Positive Givastomig Phase 1b Data at ESMO GI 2025

    GLOBENEWSWIRE

    I-Mab Publishes Givastomig Data in Cancer Research Journal

    GLOBENEWSWIRE

    I-Mab Highlights Givastomig Ph1b Gastric Cancer Data

    GLOBENEWSWIRE

    I-Mab to Host Webinar on New Givastomig Data at ESMO GI 2025

    GLOBENEWSWIRE

    I-Mab Complies with Nasdaq Minimum Bid Price Requirement

    GLOBENEWSWIRE

    I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series

    GLOBENEWSWIRE

    I-Mab to Present at Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    I-Mab Reports Q1 2025 Financial Results and Business Update

    GLOBENEWSWIRE

    I-Mab: Givastomig Abstract Accepted for ESMO GI 2025

    GLOBENEWSWIRE

    I-Mab Reports 2024 Financial Results and Business Update

    GLOBENEWSWIRE

    I-Mab to Present at Needham Healthcare Conference

    GLOBENEWSWIRE

    I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

    GLOBENEWSWIRE

    I-Mab to Participate in Leerink Partners Global Health Conference

    GLOBENEWSWIRE

    I-Mab pauses Sanofi-partnered to make play for busy CLDN18.2

    FIERCE BIOTECH

    I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

    PR NEWSWIRE

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    PR NEWSWIRE

    I-Mab Presents Givastomig Phase 1 Data at SITC 2024

    PR NEWSWIRE

    I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

    PR NEWSWIRE

    I-Mab Presents Uliledlimab PK Data At WCLC 2024

    PR NEWSWIRE

    I-Mab To Participate In H.C. Wainwright Global Investment Conference

    PR NEWSWIRE

    I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

    PR NEWSWIRE

    I-Mab divests China business to become US-based biotech firm

    BIOSPECTRUM ASIA

    I-Mab sheds China footprint to transform into US-based biotech

    FIERCE BIOTECH

    I-Mab Announces Participation at Jefferies and Piper Conferences in November

    PR NEWSWIRE

    Felzartamab Granted Breakthrough Therapy Designation by FDA for PMN

    PR NEWSWIRE

    I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio

    PR NEWSWIRE

    I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

    PR NEWSWIRE

    I-Mab and ABL Bio Announce Latest Updates of Antibody TJ-L14B/ABL503

    PR NEWSWIRE

    I-Mab Announces Upcoming Participation at September Conferences

    PR NEWSWIRE

    I-Mab to seek approval of pediatric growth hormone deficiency drug in China

    ENDPTS

    I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

    PR NEWSWIRE

    I-Mab Announce Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig

    PR NEWSWIRE

    I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with NSCLC

    PR NEWSWIRE

    I-Mab Announces Poster Presentation CD73 Antibody Uliledlimab at ASCO 2023

    PR NEWSWIRE

    I-Mab Announces First Patient Dosed in Phase 3 Study of Lemzoparlimab

    PR NEWSWIRE

    I-Mab Reports Financial Results for the Year Ended December 31, 2022

    PR NEWSWIRE

    I-Mab to Report Full Year 2022 Financial Results on March 31, 2023

    PR NEWSWIRE

    I-Mab Receives “A” Rating in Updated MSCI ESG Assessment

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.